EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Efficacy and Safety of Olipudase Alfa for the Treatment of Acid Sphingomyelinase Deficiency ( ASMD ): A Systematic Review and Meta‐Analysis

Breno Bopp Antonello iD, Giovanna Giovacchini iD, Anna Luiza Braga Albuquerque iD, Cainã Gonçalves Rodrigues, Laura Grespan Dill, Maria Inez Dacoregio, Paulo Victor Zattar Ribeiro iD

American Journal of Medical Genetics Part A · 2026

DOI: 10.1002/ajmg.a.64258 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift American Journal of Medical Genetics Part A, 2026. Verfasst von Breno Bopp Antonello und 6 weiteren Autor:innen. Beteiligte Einrichtung: Franciscan University, Santa Maria, Brazil. Hauptthemen laut MEDLINE: Sphingomyelin Phosphodiesterase. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acid sphingomyelinase deficiency (ASMD), or Niemann–Pick disease types A, B, and A/B, is a rare lysosomal storage disorder caused by SMPD1 mutations. Clinical forms range from severe neurovisceral (type A) to chronic visceral (type B), mainly affecting the liver, spleen, and lungs. Until 2022, treatment was limited to supportive care. The approval of olipudase alfa for the non‐central nervous system (CNS) manifestations of ASMD marked a major advance, with trials showing improvements in organ volumes and lung function. This meta‐analysis evaluates the broader clinical impact of olipudase alfa in ASMD. A systematic search of Cochrane, PubMed, and Embase identified RCTs and cohort studies on olipudase alfa in patients with ASMD. Primary outcomes included mean change in %DLco, %Liver volume, and %Spleen volume; other secondary outcomes were also assessed. Study selection followed PRISMA guidelines, and statistical analyses were conducted using R software. The study was registered in PROSPERO CRD420251032281. Three studies (One RCT) encompassing 46 patients were included. Follow‐up duration ranged from 1 to 6.5 years. All patients received olipudase alfa; only one study included a placebo group. Pooled results showed a mean DLco increase of 34.63% (95% CI: 26.09–43.18), a liver volume reduction of −37.76% (95% CI: −49.78 to −25.75), and a spleen volume reduction of −49.46% (95% CI: −57.39 to −41.53) after 2 years. The olipudase alfa demonstrates substantial clinical benefits in ASMD, significantly improving lung function and reducing organomegaly. Further studies are needed to confirm long‐term safety and efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sphingomyelin PhosphodiesteraseHumansTreatment OutcomeMutationLiverRecombinant ProteinsEnzyme Replacement Therapy

Stichwörter der Autor:innen

ASMDNiemann–pick diseaseacid sphingomyelinase deficiencyenzyme replacement therapylysosomal storage disorderolipudase alfa

Substanzen

Sphingomyelin PhosphodiesteraseRecombinant ProteinsSMPD1 protein, human

Autor:innen und Institutionen

  • Franciscan University, Santa Maria, Brazil.
  • Faculty of Medicine of ABC, Santo André, Brazil.
  • Federal University of Minas Gerais, Belo Horizonte, Brazil.
  • Federal University of Ceará, Fortaleza, Brazil.
  • Federal University of Santa Maria, Santa Maria, Brazil.
  • University of São Paulo, São Paulo, Brazil.

ORCID-Profile: Breno Bopp Antonello, Giovanna Giovacchini, Anna Luiza Braga Albuquerque, Paulo Victor Zattar Ribeiro

Zitieren

APA

Antonello, B. B., Giovacchini, G., Albuquerque, A. L. B., Rodrigues, C. G., Dill, L. G., Dacoregio, M. I., & Ribeiro, P. V. Z. (2026). Efficacy and Safety of Olipudase Alfa for the Treatment of Acid Sphingomyelinase Deficiency ( ASMD ): A Systematic Review and Meta‐Analysis. American Journal of Medical Genetics Part A. https://doi.org/10.1002/ajmg.a.64258

Vancouver

Antonello BB, Giovacchini G, Albuquerque ALB, Rodrigues CG, Dill LG, Dacoregio MI, et al. Efficacy and Safety of Olipudase Alfa for the Treatment of Acid Sphingomyelinase Deficiency ( ASMD ): A Systematic Review and Meta‐Analysis. American Journal of Medical Genetics Part A. 2026. doi:10.1002/ajmg.a.64258

BibTeX
@article{Antonello2026,
  author = {Antonello, Breno Bopp and Giovacchini, Giovanna and Albuquerque, Anna Luiza Braga and Rodrigues, Cainã Gonçalves and Dill, Laura Grespan and Dacoregio, Maria Inez and Ribeiro, Paulo Victor Zattar},
  title = {Efficacy and Safety of Olipudase Alfa for the Treatment of Acid Sphingomyelinase Deficiency ( ASMD ): A Systematic Review and Meta‐Analysis},
  journal = {American Journal of Medical Genetics Part A},
  year = {2026},
  doi = {10.1002/ajmg.a.64258}
}
Kostenlos starten →